Premium
Restenosis after PCI : Battered but not beaten
Author(s) -
Safian Robert D.
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26420
Subject(s) - medicine , conventional pci , restenosis , medical emergency , coronary restenosis , cardiology , stent , myocardial infarction
Key Points In patients with bare‐metal stent (BMS) restenosis, drug‐eluting stents (DES) are superior to vascular brachytherapy (VBT), leading to a lower risk of clinical restenosis and target vessel revascularization, but not to less stent thrombosis, myocardial infarction, or death; these benefits persist for 2–5 years. The optimal management of DES restenosis is unknown, but recent studies suggest that drug‐eluting balloons (DEB) and DES have similar efficacy and safety. Since DEB are not commercially available in the United States, VBT may be a reasonable alternative to repeated DES.